Summary: In a phase 2, double-blind, placebo-controlled, dose-ranging trial of 901 adults with type 2 diabetes (n=512) or obesity (n=389), the oral small-molecule GLP-1 receptor agonist lotiglipron lowered HbA1c by up to 1.44% and body weight by up to 7.47% versus placebo. The trial was stopped early after transaminase elevations (6.6% and 6.0% on drug versus 1.6% on placebo), and clinical development was terminated.
PICO Summary
| Element | Detail |
|---|---|
| Population | 901 adults treated with at least one dose in a phase 2, randomized, double-blind, multicentre study: a type 2 diabetes cohort (n=512) and an obesity cohort (n=389). The trial was terminated early for safety, and most participants assigned to higher doses did not reach their target maintenance dose. |
| Intervention | Lotiglipron (PF-07081532), a once-daily oral small-molecule GLP-1 receptor agonist, given across a range of doses with titration (for example, 80 mg in the diabetes cohort and up to 200 mg in the obesity cohort). |
| Comparison | Matched placebo within each cohort. |
| Outcome | Type 2 diabetes cohort, HbA1c at week 16: least squares mean change up to -1.44% (90% CI -1.63 to -1.26) with lotiglipron 80 mg versus -0.07% (90% CI -0.25 to 0.11) with placebo (p<0.0001 across doses). Obesity cohort, body weight at week 20: up to -7.47% (90% CI -8.50 to -6.43) with lotiglipron 200 mg (five-step titration) versus -1.84% (90% CI -2.85 to -0.83) with placebo (p<0.01 across doses). Transaminase elevations occurred in 6.6% (diabetes) and 6.0% (obesity) on lotiglipron versus 1.6% on placebo; nausea was the most common adverse event. No ARR or NNT was reported. Note that confidence intervals are 90%, not 95%. |
Lotiglipron oral GLP-1 RA in T2D and obesity
Phase 2 RCT · T2D and obesity · 16-20 weeks
Lotiglipron produced dose-dependent HbA1c and weight reductions, but transaminase elevations stopped the trial early and ended its development. Not available for use.
Expert Commentary
This trial is best read as a cautionary tale rather than a success story. The efficacy signals are real and dose-dependent, with HbA1c and weight reductions that sit in the range expected of an effective GLP-1 receptor agonist, and the placebo-controlled design supports those estimates. The verdict, however, is that lotiglipron failed as a clinical candidate: an unexplained hepatotoxic signal forced early termination, the analysis plan was modified before unblinding, and most participants on higher doses never reached their intended maintenance dose, so the reported effects probably understate the molecule’s ceiling while the safety concern remains its defining feature. The chief limitation is that early stoppage and incomplete titration leave both efficacy and the transaminase signal imprecisely characterised, with attempts to identify an at-risk subgroup unsuccessful. Confidence intervals are reported at 90%, and the study was funded and conducted by the manufacturer, which warrants the usual caution. Can I use this with my patients? No. Lotiglipron is not available and its development has been halted, so there is nothing here to prescribe. The value for practice is conceptual: it is a reminder that oral small-molecule GLP-1 agents must clear a hepatic safety bar, and clinicians should keep that lens when newer oral agents in this class reach the clinic.
References
Amin NB, Frederich R, Tsamandouras N, Haggag AZ, Schuster T, Zmuda W, et al. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: a dose-ranging, phase 2, randomized, placebo-controlled study. Diabetes Obes Metab. 2025;27(1):215-227. doi:10.1111/dom.16005